Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications.
暂无分享,去创建一个
Marianne Paesmans | Jean Klastersky | M. Paesmans | J. Klastersky | A. Georgala | M. Aoun | Aspasia Georgala | Frédérique Muanza | Barbara Plehiers | Laurent Dubreucq | Yassine Lalami | Michel Aoun | Martine Barette | M. Barette | Y. Lalami | F. Muanza | B. Plehiers | L. Dubreucq
[1] L. Young,et al. Erratum: Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever (J. Infec. Dis. 1990; 161:381-396) , 1990 .
[2] L. Young,et al. GUIDELINES FROM THE INFECTIOUS DISEASES SOCIETY OF AMERICA 1997 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Unexplained Fever , 1997 .
[3] W. Khan,et al. Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. , 1995, The American journal of medicine.
[4] R. Finberg,et al. Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] L. Elting,et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] R. Finberg,et al. Fever and neutropenia--how to use a new treatment strategy. , 1999, The New England journal of medicine.
[7] R. Mayer,et al. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. , 1988, Archives of internal medicine.
[8] L. Young,et al. From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. , 1990, The Journal of infectious diseases.
[9] R. Benjamin,et al. Outpatient treatment of febrile episodes in low‐risk neutropenic patients with cancer , 1993, Cancer.
[10] R. Finberg,et al. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] L. Young,et al. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] L. Elting,et al. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] M. O'Ryan,et al. Prospective evaluation of a model of prediction of invasive bacterial infection risk among children with cancer, fever, and neutropenia. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[14] M. Paesmans,et al. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. , 1999, The New England journal of medicine.
[15] P. Clark,et al. Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study , 2003, British Journal of Cancer.
[16] S. Steinberg,et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. , 1999, The New England journal of medicine.
[17] B. Rapoport,et al. Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score , 2004, Supportive Care in Cancer.
[18] T. Calandra,et al. Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer , 2002 .
[19] M. Paesmans,et al. Methodology for clinical trials involving patients with cancer who have febrile neutropenia: updated guidelines of the Immunocompromised Host Society/Multinational Association for Supportive Care in Cancer, with emphasis on outpatient studies. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.